Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Conversion of the convertible bond entered into between Nexstim Plc and Bracknor to shares and issuance of shares pursuant to the financing arrangement announced on 21 July 2016


Posted on: 22 Nov 16

 

Company announcement, Helsinki, 22 November 2016 at 5 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, pursuant to the authorisations received from the Company's Extraordinary General Meeting on 18 August 2016 and the financing arrangement entered into with Bracknor Investment which was announced on 21 July, the Board of Directors of the Company has today resolved to approve Bracknor's request to convert EUR 740,000 of the convertible bond to Company's shares at issue price of EUR 0.22406.  The Board of Director's has resolved to transfer a total of 3,302,686 new shares of the Company to Bracknor and to list the new shares issued. The new shares will be listed approximately on 28th November 2016. After the issuance, the total number of shares in the Company is 27,075,858.

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone:

Nexstim                                                                                                                                    +447715163942
Martin Jamieson, Chairman and CEO                                                   martin.jamieson@nexstim.com
                                                                                                                                                                                
UB Securities Oy (Certified Adviser)                                                                         +358 (0)9 2538 0246

Consilium Strategic Communications                                                                     +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton                           nexstim@consilium-comms.com

About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

 

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/5b92fde8-b0fa-4e87-b8cf-f0c6101e19e3

GlobeNewswire
globenewswire.com

Last updated on: 23/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.